Journal: International Journal of Molecular Sciences

Article Title: Study on the Chemical Composition and Multidrug Resistance Reversal Activity of Euphorbia uralensis (Euphorbiaceae)

doi: 10.3390/ijms26010412

Figure Lengend Snippet: Schematic diagram of molecular docking of EUD-17, verapamil, and ABCB1 protein (binding energy ≤ −5 kcal/mol). Note: A. Alkyl and Pi-Alkyl are shown as pink dashed lines. B. carbon hydrogen bond is shown as green dashed line; Pi-sigma is shown as purple dashed line; Pi-Pi T-shaped is shown as dark pink dashed line; alkyl and Pi-alkyl are shown as light pink dashed lines.

Article Snippet: Petroleum ether, dichloromethane, ethyl acetate, and n-butyl alcohol were purchased from Tianjin Fuyu Fine Chemical Co., Ltd. (Tianjin, China). β -actin antibody and PVDF membrane were obtained from Merck KGaA (Darmstadt, Germany), and the ABCB1 antibody was purchased from MedChemExpress, USA.

Techniques: Protein Binding

Journal: International Journal of Molecular Sciences

Article Title: Study on the Chemical Composition and Multidrug Resistance Reversal Activity of Euphorbia uralensis (Euphorbiaceae)

doi: 10.3390/ijms26010412

Figure Lengend Snippet: RMSD of complexes, proteins, and ligands: verapamil ( A ), EUD-17 ( D ), verapamil ( B ) and EUD-17 ( E ) with ABCB1 protein; Verapamil ( C ), EUD-17 ( F ) with ABCB1 protein Rg; Spacing of verapamil ( G ), EUD-17 ( J ) small molecules with ABCB1 protein binding sites; Simulated conformational superposition of verapamil ( H ), EUD-17 ( K ) with ABCB1 protein; The relationship between verapamil ( I ), EUD-17 ( L ), and the number of hydrogen bonds in the ABCB1 protein complexes.

Article Snippet: Petroleum ether, dichloromethane, ethyl acetate, and n-butyl alcohol were purchased from Tianjin Fuyu Fine Chemical Co., Ltd. (Tianjin, China). β -actin antibody and PVDF membrane were obtained from Merck KGaA (Darmstadt, Germany), and the ABCB1 antibody was purchased from MedChemExpress, USA.

Techniques: Protein Binding

Journal: International Journal of Molecular Sciences

Article Title: Study on the Chemical Composition and Multidrug Resistance Reversal Activity of Euphorbia uralensis (Euphorbiaceae)

doi: 10.3390/ijms26010412

Figure Lengend Snippet: Effects of compounds EUD-17 on ABCB1 protein expression levels in MCF-7/ADR cells (treated group vs. model group, **** p < 0.0001).

Article Snippet: Petroleum ether, dichloromethane, ethyl acetate, and n-butyl alcohol were purchased from Tianjin Fuyu Fine Chemical Co., Ltd. (Tianjin, China). β -actin antibody and PVDF membrane were obtained from Merck KGaA (Darmstadt, Germany), and the ABCB1 antibody was purchased from MedChemExpress, USA.

Techniques: Expressing

Journal: Gene

Article Title: Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.

doi: 10.1016/j.gene.2021.146003

Figure Lengend Snippet: Fig. 5. Overexpression of PER2 regulates clock circadian and ameliorates drug resistance through PI3K/AKT pathway in DDP-resistant cervical cancer cells. (A) Representative images of western blot. (B-M) Quantitative results of (B, C) PER2, (D, E) CLOCK, (F, G) BMAL1, (H, I) CRY1, (J, K) MRP1 and (L, M) MDR1 in Hela/ DDP as well as SiHa/DDP cells with pcDNA3.1-PER2 transfection and/or hEGF treatment. **P < 0.01; ****p < 0.0001.

Article Snippet: The sample was transferred onto the membrane at a gel volume of 1.5 mA/cm2 for 1.5 h. The membrane was added with 5% skimmed milk powder + TBST, and shaken in a shaker at room temperature lasting 1 h. The membranes were added with primary antibodies against PER2 (67513-1-Ig; Proteintech), CLOCK (18094-1-AP; Proteintech), BMAL1 (14268-1-AP; Proteintech), CRY1 (13474-1-AP; Proteintech), MRP1 (67228–1-Ig; Proteintech), MDR1 (22336-1-AP; Proteintech), PI3K (20584-1-AP; Proteintech), p-PI3K (17366S; CST), AKT (10176-2-AP; Proteintech), p-AKT (66444-1-Ig; Proteintech), Snail1 (13099-1-AP; Proteintech), Twist (25465–1-AP; Proteintech), E-cadherin (20874-1- AP; Proteintech), Vimentin (10366-1-AP; Proteintech) and GAPDH (60004-1-Ig; Proteintech) which was diluted at 1:1000 with 5% BSA + TBS, and shaken overnight at 4 ◦C.

Techniques: Over Expression, Western Blot, Transfection

Journal: Gene

Article Title: Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer.

doi: 10.1016/j.gene.2021.146003

Figure Lengend Snippet: Fig. 9. Cisplatin therapy at the peak of PER2 expression ameliorates chemotherapy resistance and EMT in cervical cancer. (A) Representative images of western blot. Assessment of the expression of (B) PER2, (C) CLOCK, (D) BMAL1, (E) CRY1, (F) MRY1, (G) MRP1, (H) PI3K, (I) p-PI3K, (J) p-PI3K/PI3K, (K) AKT, (L) p-AKT, (M) p- AKT/AKT, (N) Snail, (O) Twist, (P) Vimentin and (Q) E-cadherin in tumor tissues from Hela/DDP cells-induced nude mice treated with Cisplatin at the peak or trough of PER2 expression. *P < 0.05; **p < 0.01; ***p < 0.001.

Article Snippet: The sample was transferred onto the membrane at a gel volume of 1.5 mA/cm2 for 1.5 h. The membrane was added with 5% skimmed milk powder + TBST, and shaken in a shaker at room temperature lasting 1 h. The membranes were added with primary antibodies against PER2 (67513-1-Ig; Proteintech), CLOCK (18094-1-AP; Proteintech), BMAL1 (14268-1-AP; Proteintech), CRY1 (13474-1-AP; Proteintech), MRP1 (67228–1-Ig; Proteintech), MDR1 (22336-1-AP; Proteintech), PI3K (20584-1-AP; Proteintech), p-PI3K (17366S; CST), AKT (10176-2-AP; Proteintech), p-AKT (66444-1-Ig; Proteintech), Snail1 (13099-1-AP; Proteintech), Twist (25465–1-AP; Proteintech), E-cadherin (20874-1- AP; Proteintech), Vimentin (10366-1-AP; Proteintech) and GAPDH (60004-1-Ig; Proteintech) which was diluted at 1:1000 with 5% BSA + TBS, and shaken overnight at 4 ◦C.

Techniques: Expressing, Western Blot

Journal: Annals of Translational Medicine

Article Title: Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor

doi: 10.21037/atm-21-4199

Figure Lengend Snippet: Primer sequence of the genes for qRT-PCR analysis (5'–3')

Article Snippet: The primary antibodies included the following: PXR antibody (1:50, 15607-1-AP, Proteintech, USA), MDR1 antibody (1:50, AF5185, Affinity, USA), BCRP antibody (1:50, AF5177, Affinity, USA), and CYP3A4 antibody (1:50, 18227-1-AP, Proteintech, USA).

Techniques: Sequencing

Journal: Annals of Translational Medicine

Article Title: Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor

doi: 10.21037/atm-21-4199

Figure Lengend Snippet: Effect of PECZ on the mRNA expression of drug resistance genes. The mRNA expressions of PXR (A), MDR1 (B), BCRP (C), and CYP3A4 (D) in MDA-MB-231/docetaxel cells were detected by qRT-PCR. (x¯±s, n=3), *, P<0.05; **, P<0.01 vs. control group. PECZ, petroleum ether extracts of Curcuma zedoaria; PXR, pregnane X receptor; MDR1, multidrug resistance 1; BCRP, breast cancer resistance protein; CYP3A4, cytochrome P-450.

Article Snippet: The primary antibodies included the following: PXR antibody (1:50, 15607-1-AP, Proteintech, USA), MDR1 antibody (1:50, AF5185, Affinity, USA), BCRP antibody (1:50, AF5177, Affinity, USA), and CYP3A4 antibody (1:50, 18227-1-AP, Proteintech, USA).

Techniques: Expressing, Quantitative RT-PCR

Journal: Annals of Translational Medicine

Article Title: Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor

doi: 10.21037/atm-21-4199

Figure Lengend Snippet: Effect of PECZ on the protein expression of drug resistance genes in MDA-MB-231/docetaxel cells. Representative band of each protein (A). Relative protein expression of PXR (B), MDR1 (C), BCRP (D), and CYP3A4 (E). (x¯±s, n=3), *, P<0.05; **, P<0.01 vs. control group. PECZ, petroleum ether extracts of Curcuma zedoaria; PXR, pregnane X receptor; MDR1, multidrug resistance 1; BCRP, breast cancer resistance protein; CYP3A4, cytochrome P-450.

Article Snippet: The primary antibodies included the following: PXR antibody (1:50, 15607-1-AP, Proteintech, USA), MDR1 antibody (1:50, AF5185, Affinity, USA), BCRP antibody (1:50, AF5177, Affinity, USA), and CYP3A4 antibody (1:50, 18227-1-AP, Proteintech, USA).

Techniques: Expressing

Journal: Annals of Translational Medicine

Article Title: Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor

doi: 10.21037/atm-21-4199

Figure Lengend Snippet: PECZ and docetaxel decreased the expression of drug resistance genes. Representative images of immunohistochemical showing PXR, MDR1, CYP3A4, and BCRP in tumor tissues in the different groups. Original magnification ×200, ×400; (x¯±s, n=3). PECZ, petroleum ether extracts of Curcuma zedoaria; PXR, pregnane X receptor; MDR1, multidrug resistance 1; BCRP, breast cancer resistance protein; CYP3A4, cytochrome P-450.

Article Snippet: The primary antibodies included the following: PXR antibody (1:50, 15607-1-AP, Proteintech, USA), MDR1 antibody (1:50, AF5185, Affinity, USA), BCRP antibody (1:50, AF5177, Affinity, USA), and CYP3A4 antibody (1:50, 18227-1-AP, Proteintech, USA).

Techniques: Expressing, Immunohistochemical staining

Journal: Annals of Translational Medicine

Article Title: Curcuma zedoaria petroleum ether extract reverses the resistance of triple-negative breast cancer to docetaxel via pregnane X receptor

doi: 10.21037/atm-21-4199

Figure Lengend Snippet: PECZ reduced the mRNA and protein expressions of drug resistance genes in tumor tissues. Effect of PECZ and docetaxel on the mRNA expressions of PXR (A), MDR1 (B), BCRP (C), and CYP3A4 (D) in tumor tissues. Representative band of each protein (E). Effect of PECZ and docetaxel on the protein expressions of PXR (F), MDR1 (G), BCRP (H), and CYP3A4 (I) in tumor tissues. (x¯±s, n=3); *, P<0.05; **, P<0.01 vs. model group. PECZ, petroleum ether extracts of Curcuma zedoaria; PXR, pregnane X receptor; MDR1, multidrug resistance 1; BCRP, breast cancer resistance protein; CYP3A4, cytochrome P-450.

Article Snippet: The primary antibodies included the following: PXR antibody (1:50, 15607-1-AP, Proteintech, USA), MDR1 antibody (1:50, AF5185, Affinity, USA), BCRP antibody (1:50, AF5177, Affinity, USA), and CYP3A4 antibody (1:50, 18227-1-AP, Proteintech, USA).

Techniques: